Get the Stockscreener App
3.4292
1.88%
-0.0658
X 4 Pharmaceuticals Inc stock is traded at $3.4292, with a volume of 412.06K.
It is down -1.88% in the last 24 hours and down -15.11% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$3.495
Open:
$3.52
24h Volume:
412.06K
Relative Volume:
0.49
Market Cap:
$339.08M
Revenue:
$9.01M
Net Income/Loss:
$-99.72M
P/E Ratio:
-0.7556
EPS:
-4.5381
Net Cash Flow:
$-92.85M
1W Performance:
-5.27%
1M Performance:
-15.11%
6M Performance:
-19.87%
1Y Performance:
+1.46%
1-Day Range:
$3.40
$3.57
1-Week Range:
$3.355
$3.65
52-Week Range:
$2.80
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.42 | 347.01M | 9.01M | -99.72M | -92.85M | -4.5381 |
VRTX
Vertex Pharmaceuticals Inc
|
521.80 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
808.42 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.67 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
973.22 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
364.48 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | Guggenheim | Buy |
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
X4 Pharmaceuticals, Inc. (XFOR) Latest Stock News & Headlines - Yahoo Finance
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Madrigal Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq
X4 Pharmaceuticals at Wells Fargo conference: trial reset lifts outlook By Investing.com - Investing.com India
XFOR: Phase III enrollment for mavorixafor nears completion, with data and launch expected by early 2029 - TradingView
X4 Pharmaceuticals (NASDAQ: XFOR) Secures FDA Approval for Reduced Sample Size in 4WARD Trial, Data Expected in Early 2028 - Kalkine Media
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference - markets.businessinsider.com
Wells Fargo’s healthcare conference will include an X4 Pharmaceuticals talk Sept. 10 - Stock Titan
X4 Pharmaceuticals Advances Mavorixafor Strategy in Chronic Neutropenia - TipRanks
X4 posts updated corporate presentation; full 4WARD enrollment expected Q4 2026, topline data H1 2028 - TradingView
X4 Pharmaceuticals (XFOR) outlines path to possible 2029 FDA approval - Stock Titan
Layoff Tracker: Merck adds 53 jobs to New Jersey chopping block - BioSpace
X4 Pharmaceuticals: FDA OKs Reduced Sample Size for 4WARD Phase 3, Enrollment to Finish by Year-End 2026 - TradingView
FDA backs smaller late-stage test of X4 (NASDAQ: XFOR) neutropenia drug, with pivotal data not due until 2028 - Stock Titan
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting - Yahoo Finance
X4 Pharmaceuticals Stock Price Forecast. Should You Buy XFOR? - StockInvest.us
ETFs Investing in X4 Pharmaceuticals, Inc. Stocks - tradingview.com
X4 Pharmaceuticals Inc. (XFOR) Peer Comparison – Compare with Others - Value Research
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
X4 Pharmaceuticals Inc. (XFOR) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
X4 Pharmaceuticals Inc (XFOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission - PR Newswire
Deep Track Capital, LP Boosts X4 Pharmaceuticals (XFOR) Stake by 26.84% - GuruFocus
Is OPK Worth Buying as Valuation Meets Improving Business Trends? - TradingView
X4 (XFOR) Financial Update: Profit Per Share Clears Its Benchmark in Latest Trading; Closing Reaction - vinanet.vn
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade) - Seeking Alpha
X4 (XFOR) Share-Price Review: Closes 2.09% Lower at $4.21 in the Current Update; Price-Level Context: the Near-Term Reference Band Stretches From $4.00 to $4.42 in Latest TradingChandelier Stop - vinanet.vn
Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers - Fierce Biotech
C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Study Explores Industry Growth Toward $2.75 Billion - openPR.com
Perceptive Advisors (XFOR) reports 8.1% beneficial stake in X4 Pharmaceuticals - Stock Titan
Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax - Stock Titan
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk? - TradingView
4 Best Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool
Deep Track Capital (XFOR) discloses 8.33% X4 Pharmaceuticals stake with capped warrants - Stock Titan
X4 Pharmaceuticals President John Volpone Sells 24,576 Shares to Settle Tax on RSU Award - Kalkine Media
John Volpone Sells 24,576 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock - MarketBeat
X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Sells $210,615.84 in Stock - MarketBeat
X4 Pharma chairman Craig R. sells $210,829 in shares - Investing.com
X4 Pharma chairman Craig R. sells $210,829 in shares By Investing.com - Investing.com India
X4 Pharmaceuticals Executive Chairman Adam R. Craig Sells 47,436 Shares to Cover RSU Tax Liability - Kalkine Media
X4 Pharmaceuticals, Inc SEC Filing (Aug 13, 2026) - Stock Titan
Industry Analysts Just Made A Dazzling Upgrade To Their X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Revenue Forecasts - simplywall.st
Earnings Update: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Just Reported And Analysts Are Boosting Their Estimates - webull.com
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why - Yahoo Finance
XFOR Q3 EPS Estimate Lifted by Brookline Capital Markets - marketbeat.com
Crinetics CEO exercises options for 19,928 shares | CRNX Insider Trading - Stock Titan
Equities Analysts Issue Forecasts for XFOR FY2029 Earnings - MarketBeat
X4 Pharmaceuticals Inc (XFOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
X4 Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Craig Adam R | Executive Chairman |
Aug 12 '26 |
Sale |
4.44 |
47,436 |
210,829 |
328,651 |
0.16%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):